|
NPPA releases calculation sheet for nine scheduled formulations
|
|
Our Bureau, New Delhi
June 19 , 2025
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has published the calculation sheets for the ceiling price of nine scheduled formulations under the National List of Essential Medicines (NLEM), 2022, including an antiretroviral drug, anti-inflammatory drug, antibiotic to treat tuberculosis, surface-active agent, among others.
The prices were fixed based on the Authority's earlier decision to consider data from sources such as company filing in IPDMS Form II and V, web sources, market survey or any other source, since the qualifying items as per the Pharmatrack database on some of these formulations are less than five. The prices of the nine formulations were approved in a meeting held on April 29, 2025.
According to the calculation sheet published by NPPA, price of antiretroviral drug efavirenz 60 mg capsule has been fixed at Rs. 56.66 per capsule, with 28.68 per cent reduction from the previous ceiling price. The latest ceiling price has been fixed by including the increase in the Wholesale Price Index (WPI) for the year 2023 at 0.00551% and 1.74028% for the year 2024.
Price of Hetero Healthcare's Estiva 600 mg capsule was considered for the price fixation, and monopoly conditions were applied while fixing the ceiling price.
Ceiling price of antibiotic rifampicin 300 mg tablet, used for the treatment of tuberculosis and leprosy, among others, has been reduced by 0.44% to Rs. 3.70 per tablet. The previous ceiling price for the drug including the WPI increase is Rs. 3.72 per tablet, according to the NPPA's calculation sheet.
The drug price regulator has revised or fixed the ceiling price of three formulations of 5-amino salicylic acid (mesalazine/mesalamine), used in the treatment of inflammatory bowel disease.
The Authority, in its meeting held on April 29, observed that consequent to the changes in the uploaded price of retention enema (liquid), the draft ceiling price uploaded for 5-amino salicylic acid (mesalazine/mesalamine) suppository and retention enema (foam) need to be revised due to applicability of monopoly restriction. The Price to Retailer (PTR) for these formulations were verified from Form II submitted by Sun Pharma and corrected accordingly.
However, the representation from the company that ceiling price should not be fixed for retention enema as its strength is not specified in NLEM was not agreed by the Authority as ceiling price of various such formulations have already been fixed under NLEM, 2022, said the Authority in its meeting.
Price for 5-amino salicylic acid (mesalazine/mesalamine) suppository 500 mg has been fixed at Rs 17.74 per suppository, with 17.16% reduction from the previous ceiling price. The ceiling price was increased from Rs 21.05 per suppository fixed in 2023, to Rs 21.42 per suppository on March 27, 2025.
The particular formulation is manufactured by Sun Pharma Laboratories and the authority has also imposed a Rs. 1.79 reduction as per the monopoly conditions. The PTR was revised based on the Form V filed by the company with the Authority. It may be noted that the price proposed through a draft calculation sheet in April, this year, was Rs. 16.09 per suppository.
Ceiling price of 5-amino salicylic acid (mesalazine/mesalamine) retention enema (foam) has been fixed at Rs 17 per gram. Considering the price of Cipla's formulation, the Authority has also imposed a Rs. 1.71 reduction as per monopoly conditions for the formulation. The draft calculation sheet issued in April had the price proposed as Rs. 15.42 per gram.
Ceiling price of 5-amino salicylic acid (mesalazine/mesalamine) retention enema (liquid) has been fixed at Rs 2.16 per ml, after considering the price of the formulation from two companies with market share of one per cent and above. The price proposed in the draft calculation sheet was Rs 1.74 per ml.
Price of betamethasone valerate gel 0.05%, used for the treatment of skin diseases, has been revised 28.63% down to Rs. 0.48 per gram, while the previous ceiling price was at Rs. 0.67 per gram, fixed on March 27, 2025 with the WPI increase. Average rate of reduction under the monopoly clause for the formulation, marketed by Micro Labs Ltd, has been fixed as 3.74%, according to the calculation sheet issued by the Authority now.
Price of only one product from Micro Labs has been considered for fixing the price, and the average rate of reduction under the monopoly condition for the formulation is at 3.74%.
Ceiling price of betamethasone valerate lotion 0.05 has been fixed at Rs. 0.67 per ML.
The price of nonsteroidal anti-inflammatory drug (NSAID) Ibuprofen 400 mg capsule has been reduced by 0.22 per cent to Rs. 1.33 per capsule.
The NPPA has also revised the ceiling price of surfactant in the form of suspension for intratracheal instillation, at 80.37 per mg of phospholipids in the pack, with a reduction of 5.14 per cent from the previous ceiling price.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|